[The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension].

Authors:
Dr. Hong Jiang, MD, PHD
Dr. Hong Jiang, MD, PHD
University of Louisville
Cancer Immunology
Louisville, Kentucky | United States

Zhonghua Nei Ke Za Zhi 2013 Sep;52(9):749-52

Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China.

Objective: To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension.

Methods: This was an open clinical trial with 2 weeks of placebo run-in period. A total of 74 patients with blood pressure (140-180/95-110 mm Hg (1 mm Hg = 0.133 kPa) were treated by aranidipine (5 mg/d) for 4 weeks.If clinical sitting blood pressure < 140/90 mm Hg at 4th week, aranidipine at 5 mg/d would be continued for another 8 weeks.If not, the dosage would be increased to 10 mg/d.If blood pressure <140/90 mm Hg at 8th week, aranidipine at 5 mg/d or 10 mg/d would be given constantly.If not, the dosage would be increased to 20 mg/d and given for another 4 weeks. All patients performed 24 h ambulatory blood pressure monitoring (ABPM) before and after the treatment with BPV evaluated by the average 24 h per unit time blood pressure standard deviation and morning blood pressure surge (MBPS).

Results: (1) After 12 weeks' treatment with aranidipine, the mean 24 h blood pressure was reduced significantly compared with the baseline [(14 ± 13)/(11 ± 9) mm Hg, both P < 0.05] with trough/peak (T/P) ratio of SBP and DBP in responders of 75.31% and 78.15%, respectively.(2) After 12 weeks' treatment, standard deviations of 24 h, daytime SBP/DBP and nighttime SBP/DBP were reduced significantly[(25 ± 3)/(14 ± 4) mm Hg vs (11 ± 3)/(8 ± 2) mm Hg, (24 ± 5)/(14 ± 4) mm Hg vs (11 ± 3)/(8 ± 2) mm Hg, (10 ± 3)/(8 ± 4) mm Hg vs (8 ± 3)/(6 ± 3) mm Hg], respectively with all P < 0.05.Significant decrease was shown in MBPS compared to the baseline [(27 ± 11) mm Hg vs (19 ± 9) mm Hg, P < 0.05]. (3) The incidence of adverse events was 13.4%, including mild dizziness, flushing and palpitation.

Conclusion: Administration of aranidipine enteric-coated capsules can control 24 h blood pressure effectively and reduce BPV significantly in patients with mild to moderate essential hypertension with good safety profile.

Download full-text PDF

Source

Still can't find the full text of the article?

We can help you send a request to the authors directly.
September 2013
119 Reads

Publication Analysis

Top Keywords

blood pressure
20
moderate essential
8
mild moderate
8
aranidipine mg/d
8
patients mild
8
blood
6
pressure
5
patients blood
4
pressure 140-180/95-110
4
0133 kpa
4
140-180/95-110 0133
4
total patients
4
run-in period
4
open clinical
4
hypertensionmethods open
4
essential hypertensionmethods
4
trial weeks
4
weeks placebo
4
kpa treated
4
placebo run-in
4

Similar Publications